Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Waldmann

Showing results (51-60 of 2,585) with videos related to

Pageof 259
Sort By:
Nature Reviews. Immunology|July 27, 2006
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designThomas A Waldmann
Oncogene|May 29, 2007
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphomaT A Waldmann
Cancer Surveys|January 1, 1989
IL-2 receptor expression in the haematologic malignancies: a target for immunotherapyT A Waldmann
Annual Review of Medicine|January 18, 2006
Effective cancer therapy through immunomodulationThomas A Waldmann
Annual Review of Immunology|October 3, 2002
The meandering 45-year odyssey of a clinical immunologistThomas A Waldmann
Expert Review of Clinical Immunology|November 1, 2014
Interleukin-15 in the treatment of cancerThomas A Waldmann
Psychonomic Bulletin & Review|November 10, 2001
Predictive versus diagnostic causal learning: evidence from an overshadowing paradigmM R Waldmann
Trends in Pharmacological Sciences|May 1, 1993
The IL-2/IL-2 receptor system: a target for rational immune interventionT A Waldmann
Journal of the National Cancer Institute|June 21, 1989
Multichain interleukin-2 receptor: a target for immunotherapy in lymphomaT A Waldmann
Advances in Experimental Medicine and Biology|January 1, 1987
The interleukin-2 receptor on normal and malignant lymphocytesT A Waldmann
Pageof 259

Showing results (51-60 of 2,585) with videos related to

Sort By:
Pageof 259
Nature Reviews. Immunology|July 27, 2006
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designThomas A Waldmann
Oncogene|May 29, 2007
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphomaT A Waldmann
Cancer Surveys|January 1, 1989
IL-2 receptor expression in the haematologic malignancies: a target for immunotherapyT A Waldmann
Annual Review of Medicine|January 18, 2006
Effective cancer therapy through immunomodulationThomas A Waldmann
Annual Review of Immunology|October 3, 2002
The meandering 45-year odyssey of a clinical immunologistThomas A Waldmann
Expert Review of Clinical Immunology|November 1, 2014
Interleukin-15 in the treatment of cancerThomas A Waldmann
Psychonomic Bulletin & Review|November 10, 2001
Predictive versus diagnostic causal learning: evidence from an overshadowing paradigmM R Waldmann
Trends in Pharmacological Sciences|May 1, 1993
The IL-2/IL-2 receptor system: a target for rational immune interventionT A Waldmann
Journal of the National Cancer Institute|June 21, 1989
Multichain interleukin-2 receptor: a target for immunotherapy in lymphomaT A Waldmann
Advances in Experimental Medicine and Biology|January 1, 1987
The interleukin-2 receptor on normal and malignant lymphocytesT A Waldmann
Pageof 259